BioSpace News Archive

The changes are unlikely to help people in developing countries but could reduce innovation among biopharma companies and ultimately do more harm than good.

VIDA Diagnostics, Inc., the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials.

ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery presented new preclinical data from the company’s inhaled mRNA-based molecular therapy program for the treatment of primary ciliary dyskinesia in three posters at the American Thoracic Society 2022 International Conference, taking place May 13-18, 2022 in San Francisco.

Full results from the positive MANDALA Phase III trial showed that PT027 at two different strengths of budesonide, an inhaled corticosteroid, used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.

Inmagene Biopharmaceuticals announces that the U.S. Food and Drug Administration cleared its investigational new drug application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase inhibitor, to proceed to the Phase I clinical trial.

GeneQuantum Healthcare Co., Ltd. announced that two of the company’s bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum’s pipelines in the clinical stage.

Antengene Corporation Limited announces that its first commercialized product, the oral XPO1 inhibitor XPOVIO® approved for the treatment of relapsed/refractory multiple myeloma, has officially entered multiple hospitals, online-hospitals, and direct-to-patient pharmacies in mainland China.

Researchers will be presenting these prostate cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association.

StageZero Life Sciences, Ltd. announced the worldwide launch of the COC Plus Program for patients currently in the COC Protocol / TREAT Program.

Boehringer Ingelheim announced Phase II data for BI 1015550, a novel investigational phosphodiesterase 4B inhibitor, that was published in The New England Journal of Medicine.